Business
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuitAccess video here SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and
About this update from Senti Biosciences Holdings, Inc.
[{"type":"image","alt":"Senti Biosciences, Inc.","displaySize":"","headline":null,"caption":"Senti Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LwHg6RoZ4drUhxxgTNKbZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf","width":166,"height":42}},"lazy":false},{"type":"text","content":"Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit","length":274,"tagName":"p"},{"type":"text","content":"Access video here","length":17,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announces the release of its new animated video for its lead asset in development, SENTI-202. The video can be accessed here.","length":399,"tagName":"p"},{"type":"text","content":"SENTI-202 is the Company’s First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 has three main components:","length":362,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"OR Logic Gate “Kills” leukemia blasts and LSCs via CD33 OR FLT3 activating CAR (aCAR)","length":86,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CD33 and/or FLT3 expressed in ~95% of AML patients with CD33 being predominantly expressed on bulk blasts and FLT3 on LSCs","length":123,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":123,"olType":false}]},{"val":[{"type":"text","content":"NOT Logic Gate “Protects” healthy HSC/HSPCs from ‘off-tumor, on-target’ effects","length":80,"tag...